H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on OpGen Inc (NASDAQ: OPGN) today and set a price target of $6. The company’s shares closed yesterday at $1.22, close to its 52-week low of $1.18.
According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -13.5% and a 25.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, Synergy Pharmaceuticals Inc, and Bausch Health Companies Inc.
Currently, the analyst consensus on OpGen Inc is a Moderate Buy with an average price target of $8.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.30 and a one-year low of $1.18. Currently, OpGen Inc has an average volume of 126.5K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OpGen, Inc. operates as a precision medicine company using molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for global healthcare settings, helping to guide clinicians with more rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. The company was founded on January 22, 2001 and is headquartered in Gaithersburg, MD.
